•Recent studies have shown strong association between obesity and psoriasis (PsO) disease activity that may lead to implications in disease management. •The objective of this study is to examine the association between body mass index (BMI) (an index for adiposity) and PsO disease severity in an observational cohort of PsO patients.
Association between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry
Patients at Risk for Psoriatic Arthritis Among Those With Psoriasis: Analysis From the Corrona Psoriasis Registry
•Undiagnosed psoriatic arthritis (PsA) remains high in patients with psoriasis (PsO); a meta-analysis reported that between 10.1%and 15.5% of patients with PsO seen by dermatologists in hospital settings may have undiagnosed PsA o In a large, observational cohort of 1511 patients with PsO in Germany, 20.6% of patients had PsA, which was newly diagnosed in 85% of cases o Of 949 patients with PsO evaluated at 34 dermatology centers across 7 countries in North America and Europe, 285 (30%) had PsA, 117 (41%) of whom were not previously diagnosed •A delay in PsA diagnosis contributes to development of peripheral joint erosions and worse long-term physical function •Screening tools like the Psoriasis Epidemiology Screening Tool (PEST) may be helpful in aiding diagnosis in a dermatology clinic setting
Impact of Psoriasis Severity on Patient-reported Clinical Symptoms, Health-related Quality of Life, and Work Productivity Among US Patients: Real-world Data From the Corrona Psoriasis Registry
•Psoriasis is a chronic, immune-mediated disease, with key clinical symptoms including skin itching, pain, and fatigue •Previous studies have reported that increased psoriasis severity is associated with worsened patient quality of life (QoL) and reduced work productivity1-5;however, few studies have examined how the severity measures used in clinical trials are associated with QoLin the real-world setting: oOne example of such a severity measure is the Investigator’s Global Assessment (IGA) mod 2011, which has been used in clinical trials7 oAffected body surface area (BSA) is a severity measure that is widely used by physicians •The objective of this study is to gain a better understanding of the relationship between disease severity in terms of IGA and BSA and patient-reported outcomes in a real-world setting
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Demographics and Disease Characteristics in the Corrona Psoriasis Registry
•Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has significant efficacy in the treatment of moderate to severe psoriasis and psoriatic arthritis (PsA) with a favorable safety profile 1-4 •The Corrona Psoriasis Registry is an independent observational cohort to compare the safety of FDA-approved systemic treatments in moderate to severe psoriasis in the US •It is estimated that between 30–42% of patients with psoriasis have concurrent PsA; these patients can face severe outcomes including early mortality, progression of joint damage, and disability 5–7 •This presentation describes the disease and clinical characteristics of psoriasis patients with concurrent PsA treated with secukinumab and other systemic treatments at registry enrollment